Abstract Our previous study demonstrated that plateletderived growth factor-BB (PDGF-BB) increased the cell proliferation of primary rat neuronal progenitor cells (NPCs). However, whether PDGF-BB regulates neurogenesis in HIV-associated neurological disorder (HAND) remains largely unknown. In this study we demonstrated that pretreatment of NPCs with PDGF-BB restored Tat-mediated impairment of cell proliferation via activation of p38 and JNK MAPK pathways. Moreover, treatment with PDGF-BB induced inactivation of glycogen synthase kinase-3β (GSK-3β), evidenced by its phosphorylation at Ser9, this effect was significantly inhibited by the p38 and JNK inhibitors. Level of nuclear β-catenin, the primary substrate of GSK-3β, was also concomitantly increased following PDGF-BB treatment, suggesting that PDGF-BB stimulates NPC proliferation via acting on GSK-3β to promote nuclear accumulation of β-catenin. This was further validated by gain and loss of function studies using cells transfected with either the wild type or mutant GSK-3β constructs. Together these data underpin the role of GSK-3β/β-catenin as a novel target that regulates NPC proliferation mediated by PDGF-BB with implications for therapeutic intervention for reversal of impaired neurogenesis inflicted by Tat.
Introduction
HIV-associated neurological disorders (HAND) comprise a range of disease symptomatology with varying degrees of HIV-related neuropsychiatric impairments. While the advent of anti-retroviral therapy (ART) has decreased the incidence of HAND, its prevalence is actually on a rise (Gonzalez-Scarano and Martin-Garcia 2005) . Increasing lines of evidence indicates that brains of patients with HAND exhibit not only neuronal damage/loss, but also exhibit fewer adult neural stem/progenitor cells (NPCs) in the hippocampus. Such a defect could account in part, for the increased prevalence of neurological disorders observed in patients with HAND in the post-ART era.
Neurogenesis includes a process wherein new dentate granule cells that are continuously generated from NPCs are integrated into the existing hippocampal circuitry in the adult mammalian brain (Venkatesan et al. 2007 ). Both physiological and pathological stimuli are known to regulate adult hippocampal neurogenesis. It is well documented that during HIV infection, early viral protein such as the HIV transactivating protein Tat, is both released by infected cells as well as taken up by neighboring cells. Tat, in turn, has been shown to impair neurogenesis (Mishra et al. 2010) . These findings thus raise the concern that cognitive dysfunction in the HIV-infected individuals may, in part, be attributed to impaired hippocampal neurogenesis.
Neurotropic family of growth factors plays key roles in maintaining neuronal homeostasis via regulation of neurogenesis (Almeida et al. 2005; Mohapel et al. 2005) . Growth factors belonging to the platelet-derived growth factor (PDGF) family are composed of products of four gene products (A-D) that can dimerize and bind to two receptor tyrosine kinases, PDGF-αR & -βR (Li et al. 2000; Bergsten et al. 2001; Heldin et al. 2002) . Our previous study has implicated PDGF-BB as a crucial factor in the regulation of NPC proliferation (Yao et al. 2012b) . However, whether PDGF-BB regulates neurogenesis especially in the context of HAND remains largely unknown.
It is well-known that GSK-3β plays a critical role in neuronal apoptosis and neurogenesis (Mao et al. 2009; Qu et al. 2010) . Following GSK-3β inactivation, there was accumulation of its substrate-β-catenin in the nucleus. Reciprocally, in the presence of active GSK-3β, there was degradation of β-catenin. Following translocation into the nucleus, β-catenin has the capacity to bind with the transcription factors, T-cell factor/lymphoid enhancer binding factor (TCF/LEF), resulting in the promotion of cell survival and neurogenesis (Gordon and Nusse 2006; Kuwabara et al. 2009 ). Whether GSK-3β/β-catenin are involved in PDGF-BB-mediated neurogenesis in NPCs remains poorly understood.
In the current study, we demonstrate direct evidence of the involvement of PDGF-BB/PDGF-R axis in regulating NPC proliferation via a previously unidentified role of GSK-3β/β-catenin.
Materials and method

Reagents
Recombinant PDGF-BB was purchased from R&D Systems (Minneapolis, MN, USA) and Tat1-72 was obtained from UK College of Medicine, Lexington, KY. The specific p38 inhibitor SB203580 and JNK inhibitor SP600125 were purchased from Calbiochem (San Diego, CA). Tyrosine kinase inhibitor STI 571 was obtained from Novartis, Basel, Switzerland. The primary antibodies used were: p-p38, p38, p-JNK, JNK, p-GSK-3β (Ser9), Lamin B (Cell Signaling, 1:200) , and β-actin (Sigma, 1:4000).
Isolation, differentiation & characterization of NPCs
NPCs derived from the hippocampus of embryonic day18 (E18) fetus were cultured in substrate-free tissue culture T75 flasks as reported by Tian et al. and our previous study (Tian et al. 2009; Yao et al. 2012b ). Based upon our earlier studies, NPCs were treated with PDGF-BB (100 ng/ml) or HIV-1 Tat (200 ng/ml). Treatment of NPCs with pharmacological inhibitors (STI-571: 1 μM; SB203580: 20 μM; SP600125: 20 μM; GSK-3β VIII: 5 μM) for 1 h followed by exposure with Tat and/or PDGF-BB. Forty eight hours later, cells were examined for cell proliferation.
Cell proliferation
Cell proliferation was measured by CyQUANT cell proliferation assay. NPCs dissociated from neurosphere were seeded in 96-well plates at a density of 10 4 cells/well for 2 days and were pretreated with PDGF-BB for 1 h followed by subsequent treatment with Tat for 48 h. Then, 100 μl of Quant® Direct reagent was added into each well and incubated in the CO 2 incubator for 15 min. Fluorescence intensity of each well was obtained using a Dynatech MR5000 plate counter at excitation and emission wavelengths of 480 and 520 nm, respectively.
Western blotting (WB)
Treated cells were lysed using the Mammalian Cell Lysis kit (Sigma, St. Louis, MO, USA) and the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL, USA). Equal amounts of the proteins were electrophoresed in a sodium dodecyl sulfate-polyacrylamide gel (12 %) under reducing conditions followed by transfer to PVDF membranes. The blots were blocked with 5 % nonfat dry milk in TBST. Western blots were then probed with antibodies recognizing the p-p38, p38, p-JNK, JNK, p-GSK-3β (Ser9), GSK-3β, β-Catenin, Lamin B (Cell Signaling, 1:200), and β-actin (Sigma, 1:4000). The secondary antibodies were alkaline phosphatase conjugated to goat anti mouse/rabbit IgG (1:5000). Signals were detected by chemiluminescence (SuperSignal West Dura Chemiluminescent Substrate, Thermo Scientific). A single representative immunoblot for all related blots is shown in a given Figure. Immunoblot densitometry was performed using Image J (http://rsb.info. nih.gov/ij/) on blot images.
Immunocytochemistry
For immunocytochemistry, NPCs were plated on cover slips, fixed with 4 % paraformaldehyde and permeabilized with 0.3 % Triton X-100 in PBS. For β-catenin staining, after blocking, cells were then incubated with a blocking buffer followed by incubation with β-catenin antibody (1:200, Cell Signalling) overnight at 4°C. For BrdU detection, the fixed cells were incubated in 2 N HCl with 0.3 % Triton X-100 followed by neutralization with 0.1 M boric acid (pH 8.0). Cells were then incubated with a blocking buffer followed by incubation with rabbit BrdU (1:200, Santa Cruz Biotechnology, Santa Cruz, CA) antibodies overnight at 4°C. Secondary AlexaFluor 594 goat anti-rabbit gG and AlexaFluor 488 goat anti-mouse IgG, was added at a 1:500 dilution for 2 h to detect β-catenin and BrdU, followed by mounting of cells with Vectashield onto glass slides (Vector Laboratories, Burlingame, CA). Fluorescent images were acquired at RT on a Zeiss Observer. A Z1 inverted microscope was used; images were processed using AxioVs 40 Version 4.8.0.0 software (Carl Zeiss MicroImaging GmbH). Photographs were acquired using an AxioCam MRm digital camera.
Short interfering (si) RNA transfection
To confirm the roles of GSK-3β and β-Catenin signaling in PDGF-BB-mediated NPC proliferation, NPCs were transfected with either the wild-type or mutant GSK-3β vector (WT or A9) (kind gift from Dr. J.Silvio Gutkind, National Institutes of Health/NIDCR) or siRNA β-catenin (Thermo Scientific Dharmacon) using the rat stem cell Nucleofector Kit (Amaxa, Gaithersburg, MD) according to the manufacturer's instructions. Briefly, dissociated cells from neurospheres were resuspended in the transfection medium, mixed with A9 construct (0.5 μg/Well for 24-well plate) or siRNAs (100nM), and electroporated following which cells were quickly centrifuged, resuspended and plated. Cells were treated with PDGF-BB for proliferation or WB analyses at 96 h following siRNA delivery.
Statistical analysis
Data were expressed as mean ± SD. Significance of differences between control and samples treated with various drugs was determined by one-way ANOVA followed by post hoc least significant difference (LSD) test. Values of p <0.05 were taken as statistically significant
Results
PDGF-BB reversed impaired NPC proliferation mediated by Tat
Our previous study has reported that there was a concentration-dependent reduction of proliferation of NPCs in presence of Tat, with the maximal effect observed at concentrations of Tat at 200 ng/ml (Yao et al. 2012a ). This concentration of Tat was therefore used for all the experiments (Bokhari et al. 2009; Yao et al. 2009 ) and must be noted is also physiologically relevant since the level of Tat protein in the CSF is about 16 ng/ml (Westendorp et al. 1995) , while that in the serum of HIV + patients is~40 ng/ml with actual concentration at tissue sites being even higher (Westendorp et al. 1995; Xiao et al. 2000; Toborek et al. 2005; Rumbaugh et al. 2006; Eugenin et al. 2007) .
To explore the role of PDGF-BB in restoring cell proliferation, NPCs were pretreated with PDGF-BB followed by exposure of cells to Tat and assessed for proliferation. As shown in Fig. 1a PDGF-BB was able to restore Tat-mediated impairment of NPC proliferation. These results were further validated by immunostaining using the anti-BrdU antibody (Fig. 1b) .
Involvement of p38/JNK MAPKs in PDGF-BB-mediated increase of NPC proliferation
MAPK pathway has been demonstrated to play a crucial role in the proliferation of NPCs (Learish et al. 2000) . It was therefore of interest next to examine the effect of PDGF-BB on the activation of p38 and JNK in NPCs. Exposure of NPCs to PDGF-BB resulted in time-dependent activation of p38/ JNK (Fig. 2a) . Interestingly, pretreatment of NPCs with either the p38 or JNK inhibitor ameliorated PDGF-BB-mediated increased proliferation of NPCs (Fig. 2b) .
Engagement of PDGF-αR, but not -βR is critical for PDGF-BB-mediated p38 and JNK activation Since PDGF-BB mediates cell signaling through its cognate receptors PDGF-αR and -βR, we sought to examine the involvement of these receptors in PDGF-BB-mediated the increased proliferation of NPCs. Pre-treatment of NPCs with the tyrosine kinase receptor antagonist STI-571 abolished PDGF-BB-mediated increase in p38 and JNK activation, thus confirming the role of PDGF-BB/PDGF-R axis in this process (Fig. 3a) .
It is well recognized that STI-571 is not a specific antagonist for either PDGF-αR/-βR, since it can inhibit other tyrosine kinases as well. Additionally, the antagonist does not allow dissecting the individual contribution of the two receptors. As an alternative approach therefore we sought to knock down the respective receptor expression in NPCs using the siRNA strategy. Intriguingly, transfection of cells with PDGF-αR siRNA but not the -βR siRNA resulted in abrogation of PDGF-BB-mediated p38 and JNK activation (Fig. 3b-c) .
GSK-3β plays the critical role in PDGF-BB mediated proliferation of NPCs GSK-3β is an important signaling protein implicated in the translocation of several transcription factors that play a key role in the proliferation and differentiation of cells (Brunet et al. 1999) . We next sought to explore the role of GSK-3β in PDGF-BB-mediated increased of NPC proliferation. As shown in Fig. 4a , treatment of NPCs with PDGF-BB resulted in inactivation of GSK-3β as evidenced by its phosphorylation at Ser9. This inactivation by PDGF-BB was abolished in cells pretreated with the antagonist for tyrosine kinase receptor STI-571 (Fig. 4b) . Furthermore, using another genetic approach, NPCs were transfected with siRNA PDGF-αR or -βR in order to distinguish which type of PDGF receptors was involved in regulation of GSK-3β inactivation. As shown in Fig. 4c-d , transfection of cells with PDGF-αR siRNA but not the -βR siRNA resulted in abrogation of p38 and JNK activation induced by PDGF-BB. The next step was to investigate the functional role of GSK-3β inactivation in PDGF-BB-mediated increase of NPC proliferation using GSK-3β VIII or gain and loss of functions for GSK-3β. Pretreatment of NPCs with GSK-3β VIII reversed PDGF-BB-mediated increase of NPC proliferation (Fig. 4e) . Furthermore, in NPCs transfected with WT GSK-3β (Fig. 4f) , as expected, PDGF-BB induced increase of NPC proliferation, however, in cells transfected with the mutant of GSK-3β (A9), PDGF-BB failed to induce inactivation of GSK-3β, thereby resulting in failure of the ability of PDGF-BB to induce increased proliferation of NPCs.
PDGF-mediated activation of GSK-3β involves activation of p38/JNK signal
Having determined the role of p38/JNK MAPKs in PDGF-BBmediated cell proliferation, we next wanted to examine the link of these pathways with PDGF-BB-mediated inactivation of GSK-3β. Pre-treatment of NPCs with either the p38 (SB203580) or JNK inhibitor (SP600125) significantly attenuated PDGF-BB-induced GSK-3β phosphorylation, suggesting thereby that PDGF-BB-mediated inactivation of GSK-3β involved activation of the p38/JNK pathways (Fig. 5) .
Involvement of β-catenin in PDGF-BB-mediated increase of NPC proliferation
β-catenin is well recognized as an important substrate of GSK-3β signaling with a key role in neuronal survival and proliferation (Li et al. 2007; L'Episcopo et al. 2011) . Therefore, the next step was to determine the effect of PDGF-BB on the nuclear translocation of β-catenin. As shown in Fig. 6a , in the untreated cells β-catenin immunoreactivity was primarily localized in the cytosol. Intriguingly, treatment of cells with PDGF-BB resulted in nuclear accumulation of β-catenin (Fig. 6b) with concomitant decrease of β-catenin in the cytosol (Fig. 6c) . These findings were also validated by transfection of cells with the mutant GSK-3β construct (A9), which resulted in abrogation of increased accumulation of β-catenin in the nucleus following treatment with PDGF-BB (Fig. 6d) . Confirmation of the role of β-catenin in PDGF-BB-mediated NPC proliferation was performed by trasnsfecting the cells with the β-catenin siRNA. In cells transfected with the β-catenin siRNA, PDGF-BB failed to induce NPC proliferation (Fig. 6e) .
Discussion
Accumulating evidence has emerged demonstrating the vital role PDGF in the developing and adult brain (Mohapel et al. 2005) . Previous studies have demonstrated PDGF-BB mediated neuroprotection against HIV proteins Tat and gp120 as well as its ability to promote NPC proliferation (Peng et al. 2008b; Peng et al. 2008a; Yao et al. 2009; Yao et al. 2012a ). Herein we demonstrate that PDGF-BB significantly ameliorated HIV Tat-induced impairment of NPC proliferation via activation of the p38 & JNK MAPK pathways. Moreover, our findings also indicate that treatment of NPCs with PDGF-BB resulted in phosphorylation of GSK-3β on Ser9, a key inhibitory site, leading to the nuclear accumulation of β-catenin, the primary substrate of GSK-3β. The present study has identified a novel molecular target-GSK-3β/β-catenin that underlies the restoration of PDGF-BB-mediated neurogenesis.
Adult neurogenesis is a well orchestrated process involving continuous generation of the dentate granule cells from NPCs and their assimilation into the existing hippocampal circuitry (Venkatesan et al. 2007 ). Viral proteins such as Tat and gp120 have been shown to negatively affect the self-renewal capacity of the hippocampus by decreasing the proliferative rate of NPCs (Okamoto et al. 2007; Mishra et al. 2010) . These findings thus raise the speculation that cognitive impairment due to HIV infection could, in part, be attributed to impaired hippocampal neurogenesis. There is no conclusive evidence of direct neuronal infection by HIV-1, and the decreased cell proliferation of NPSc or neuronal death is considered to be a consequence of the toxic effects of viral and cellular neurotoxins that are released from virus-infected and/or activated cells (Eugenin et al. 2003; Mishra et al. 2010) . Among the viral products, HIV Tat has been shown to be Fig. 5 Involvement of p38/JNK MAPKs in PDGF-BB-mediated GSK-3β phosphorylation. Representative immunoblot of NPCs exposed to PDGF-BB in the presence of p38 inhibitor SB203580 (10 μM) or JNK inhibitor SP600125 (10 μM) for 1 h significantly was monitored for GSK-3β phosphorylation. Densitometric analysis of p-GSK-3β/GSK-3β from 4 individual experiments. **p <0.01 vs control group; #p < 0.05 vs PDGF-BB group neuroexcitatory and neurotoxic, and it continues to be implicated as a causative agent in HAND (Buscemi et al. 2007; Agrawal et al. 2012) . Tat can be both secreted from infected cells and can also be taken up by neighboring noninfected cells, including neurons (Liu et al. 2000) . It is wellrecognized that microglia/macrophages are the most commonly infected cells in the brain and serve as lifelong reservoirs for HIV (Minagar et al. 2002; Gonzalez-Scarano and Martin-Garcia 2005; Kramer-Hammerle et al. 2005) . Mounting evidence also suggests the role of astrocytes as cells permissive for virus replication, albeit as low levels (Conant et al. 1994; Brack-Werner 1999; Canki et al. 2001; Li et al. 2011; Atluri et al. 2013) .
PDGF is composed of a family of five dimeric ligands that are assembled from four gene products (PDGF A-D) and that dimerize and act via two receptor tyrosine kinases, PDGF-αR & -βR (Zauli et al. 2000; Bergsten et al. 2001; Heldin et al. 2002) . PDGF-BB has been implicated as a crucial factor in the developing postnatal rat brains (Smits et al. 1991) . Previous reports have indicated that PDGF-BB mediated increased NPC proliferation involved the ERK MAPK pathway (Yao et al. 2012a ). Furthermore, PDGF-BB pretreatment was also known to induce striatal neurogenesis in a Parkinsonian rat model of 6-hydroxydopamine lesions (Mohapel et al. 2005) . The novel finding of this report is that PDGF-BB via binding to its Through the stimulation of PDGF-Rα and PDGF-Rβ, PDGF-BB has been shown to activate various signaling pathways such as ERK, JNK and p38 MAPK in various cell lines and tissues (Seo et al. 2011; Chan et al. 2013) . Previous reports have also demonstrated that in NPCs, PDGF-BB ameliorated Tat & cocaine-mediated impairment of NPC proliferation through activation of the ERK MAPK pathway (Yao et al. 2012a) . Interestingly, in addition to ERK activation, it was also demonstrated that two other MAPK signals-p38 and JNK, were also activated by PDGF-BB in NPCs. Inhibition of these both pathways at a dose that did not impact basal proliferation of hNPCs, significantly blocked PDGF-BB-induced cell proliferation. These findings thus suggest that activation of p38 & JNK MAPK signaling is essential for mediating the pro-proliferative effects of PDGF-BB in NPCs.
P38, ERK and JNK belong to the MAPK family. It is wellknown that ERK cascade can be activated by a variety of growth factors and can transmit signals to promote cell proliferation Yao et al. 2012a ). The role of p38 and JNK MAPK signaling in NPC regulation however, has been less studied. In this study, we demonstrated that activation of p38MAPK mediated PDGF-BB-induced proliferation of NPCs. Our findings are in agreement with a previous study demonstrating curcumin-mediated stimulation of embryonic neural progenitor cells via the activation of p38 MAPK pathway (Kim et al. 2008) . Similar findings on the involvement of p38MAPK activation have also been reported in adiponectin-mediated cell proliferation in the adult rat hippocampal neural stem cells (Zhang et al. 2011) . However, there are also contradictory reports indicating that activation of p38MAPK pathway by virus env gp120 leads to suppression of proliferation of adult hNPCs (Okamoto et al. 2007) . A possible explanation for the discrepancy in the findings could be attributed to the transient versus sustained activation of p38 MAPK, which, in turn, could be due to distinct ability to recruit downstream signaling mediators.
In addition to PDGF-BB-mediated activation of p38 MAPK, another interesting finding herein was the observation that inhibition of JNK MAPK pathway resulted in reversal of PDGF-BB-mediated NPC proliferation thereby highlighting the potential role of this pathway. Our results are in agreement with previous reports implying the role of JNK activation in FGF2 (Sanalkumar et al. 2010) , angionenic factor angioproieth-1 (Rosa et al. 2010) , TNF-α (Bernardino et al. 2008 ) and ampaline CX546 (Schitine et al. 2012 )-mediated proliferation of NPCs.
Another key finding of this study was the involvement of GSK-3β/β-catenin in PDGF-BB-mediated proliferation, thereby lending credence to previous reports demonstrating GSK-3β as a key regulator of diverse cellular process including neurogenesis (Zhang et al. 2011 ). Inactivation of GSK-3β resulted in accumulation of its substrate-β-catenin in the nucleus, binding with the TCF/LEF. TCF/LEF is a group of down-stream transcription factors of the Wnt/β-catenin signal pathway that have been implicated in the survival of neuronal and glial cells (Pei et al. 2012; Salins et al. 2007; Korade and Mirnics 2011; Henderson et al. 2012) , via regulation of various cell survival-related genes, such as neurotension receptor 1 gene (Souaze et al. 2006 ) and calcium/calmodulin-dependent protein kinase IV (CamK4) (Arrazola et al. 2009 ). GSK-3β phosphorylation at Ser9 inhibits its apoptotic activity, whereas phosphorylation at Tyr216 promotes its apoptotic activity (Tang et al. 2010) . In the present study, we showed that PDGF-BB induced phosphorylation at Ser9 of GSK-3β in NPCs, which was consistent with the previous report that PDGF-CC stimulated GSK-3β phosphorylation at Ser9 (Tang et al. 2010 ). In our studies we failed to detect phosphorylation of GSK-3β at Tyr216 (data not shown). Furthermore, the effect of GSK-3β phosphorylation induced by PDGF-BB was attenuated by pretreatment of cells with either the p38 or JNK MAPK inhibitors, indicating thereby that PDGF-BB induced phosphorylation of GSK-3β at Ser9 involved activation of the p38 and JNK MAPK pathway. These finding are in agreement with a previous report demonstrating that p38MAPK directly inactivated GSK-3β by phosphorylating Ser389 in the C-terminus of GSK-3β in the brain and Fig. 7 Schematic illustration demonstrating signaling pathways involved in PDGF-BB-mediated increase in proliferation of NPCs. PDGF-BBmediated engagement of the PDGF-αR stimulated the p38/JNK pathways, which in turn, inactivated GSK-3β resulting in β-catenin translocation into the nucleus, culminating ultimately to increased proliferation of NPCs thymocytes, resulting in increased accumulation of intracellular β-catenin (Thornton et al. 2008) .
In summary, we provide herein the first evidence that PDGF-BB promoted proliferation of NPCs via activation of the p38 and JNK MAPK/GSK-3β/β-catenin signaling cascade (Fig. 7) . Our previous study has indicated that PDGF-BB restored Tat and cocaine-mediated impaired neurogenesis, suggesting thereby that PDGF-BB has the potential to reverse impaired neurogenesis in the context of HIV infection in vivo. It is critical as a next step to investigate the involvement and functionality of PDGF-BB and its signaling pathways in regulating NPC proliferation in vivo. Since impaired hippocampal neurogenesis has been implicated in HAND and other neurological disorders, based on our findings it can be extrapolated that PDGF-BB could serve as a therapeutic target for these disorders.
